MabCure Announces Agreement with the City University of New York Center for Advanced Technology to Validate & Evaluate Its Mo...
19 3월 2012 - 11:00PM
Business Wire
MabCure Inc., (OTCBB:MBCI) a leading developer of antibody based
technology for the diagnosis and treatment of Ovarian, Prostate,
Colorectal and other cancers today announced it has entered into an
agreement with the City University of New York Center for Advanced
Technology (CUNY CAT) to evaluate its monoclonal antibodies against
ovarian cancer cells as diagnostic reagents.
These antibodies were developed earlier by MBCI and have shown
significant promise in detecting ovarian cancer in blood samples
and distinguishing between cancer and benign tumors of the ovaries.
The results were presented last year at the annual meeting of the
Society of Gynecological Oncologists (SGO)
http://www.mabcure.com/MBCI-SGO.pdf
In order to further develop these antibodies as diagnostic
reagents, they will be the subject of further evaluation and
characterization at CUNY CAT. The work will be carried out in the
laboratory of Professor Paul Gottlieb at the City College of New
York’s Sophie Davis School of Biomedical Education. This
contractual agreement will permit the MBCI antibodies to be tested
and validated in an independent setting.
Following validation, the Company plans to evaluate the
performance of its antibodies in diagnosing ovarian cancer in blood
samples obtained from its completed Thai study as well as samples
obtained from patients previously admitted to the Department of
Gynecologic Oncology, Catholic University Hospital, Leuven,
Belgium.
Dr. Amnon Gonenne, CEO, stated, “MabCure looks forward to
accomplishing its goals of developing a definitive test for the
early detection of ovarian cancer, validating and expanding its
earlier results. The interaction with CUNY CAT organization gives
us the advantage not only of access to their scientific expertise,
but also to participate in the larger mission of the CAT as it
seeks to support early stage biotechnology initiatives in the
area”.
About MabCure Inc.
MabCure is a biotechnology company whose vision is to change the
perception of cancer as being a largely incurable disease. MabCure
owns proprietary technology for the creation of unique and highly
specific monoclonal antibodies (MAbs), which we plan to develop as
diagnostic tools, imaging agents, and drugs to treat lethal
cancers. MabCure’s initial goal is to develop its novel MAbs as
diagnostic tools for the detection of ovarian and prostate cancers
at an early stage, when these diseases are still localized and
highly curable. For further information visit the Company’s website
at www.mabcure.com.
This news release contains “forward-looking statements”.
Statements in this news release which are not purely historical are
forward-looking statements and include any statements regarding
beliefs, plans, expectations or intentions regarding the future.
Actual results could differ from those projected in any
forward-looking statements due to numerous factors. Such factors
include, among others, the change of business focus of the
management of the Company and the inability of the Company to
pursue its current objectives. These forward-looking statements are
made as of the date of this news release and the Company assumes no
obligation to update the forward-looking statements, or to update
the reasons why actual results could differ from those projected in
the forward-looking statements.
MabCure (CE) (USOTC:MBCI)
과거 데이터 주식 차트
부터 11월(11) 2024 으로 12월(12) 2024
MabCure (CE) (USOTC:MBCI)
과거 데이터 주식 차트
부터 12월(12) 2023 으로 12월(12) 2024
